Skip to content
Open access

Applying the Promising Zone Method to Biomarker‐Based Adaptive Designs: A Word of Caution

Sep 2026 · Pharmaceutical statistics · Vol 25 · 0 citations · 27 references
Medicine

TL;DR

It is shown that the promising zone method can produce Type I error inflation when embedded in biomarker‐based adaptive designs, with the magnitude of inflation depending on the underlying true treatment effect in the biomarker‐positive subgroup and specific design parameters such as the biomarker subgroup prevalence, the interim analysis timing, and the maximum inflation factor.

Abstract

Sample size re‐estimation based on interim data has become an increasingly important component of adaptive clinical trial designs. Many novel anti‐cancer therapies under development demonstrate enhanced efficacy in biomarker‐defined subpopulations rather than the overall population. To address the inherent uncertainty in the predictive value of biomarkers, biomarker‐based adaptive designs have gained considerable interest. Given the complexity of these designs, it is critical to evaluate whether existing sample size re‐estimation methods maintain adequate control of the overall Type I error rate. In this paper, we focus on the promising zone method applied within biomarker‐based adaptive designs. We show that the promising zone method can produce Type I error inflation when embedded in biomarker‐based adaptive designs, with the magnitude of inflation depending on the underlying true treatment effect in the biomarker‐positive subgroup and specific design parameters such as the biomarker subgroup prevalence, the interim analysis timing, and the maximum inflation factor. We derive exact analytical results for normally distributed endpoints and extend these findings to time‐to‐event (TTE) endpoints through the asymptotic normal approximation of the log‐rank test statistic, with the conclusions supported by simulation studies. We also discuss regulatory considerations for the implementation of such complex adaptive designs in confirmatory settings.

Read PDF

Similar papers

Preprint Nov 2026

Risk-matched case-control sampling and semiparametric weight calibration for efficient biomarker assessment with binary outcomes

Two-phase designs provide a cost-effective framework for biomarker studies and have been widely used to reduce the burden of collecting expensive biomarker measurements. Most methodological research has focused on efficient Phase II sampling and estimation of biomarker--outcome associations. A natural subsequent step,...

Jing-Yi Zhang, Fang-Ya Mao, Ling-Xiao Wang · 0 citations
Open access Oct 2026

An Inverse‐Selection‐Probability Weighted Approach for Real‐World Progression‐Free Survival With Left‐Truncated Clinico‐Genomic Data

ABSTRACT Next‐generation sequencing (NGS) has become a vital tool in precision medicine, revolutionizing cancer diagnosis and treatment. However, in real‐world studies where NGS defines study entry, data are often left‐truncated because patients who do not survive until sequencing are excluded. Consequently, standard s...

Yan Liu, S. W. Hyun, C. Sangli et al. · 0 citations
Open access Sep 2026

Bayesian Shrinkage Versus Frequentist Variable Selection in Small-Sample Translational Research: A Monte Carlo Simulation Study Grounded in Regenerative Medicine Biomarker Discovery

Introduction. Observational studies in regenerative medicine represent a promising frontier for the discovery of predictive biomarkers of therapeutic response, yet are structurally constrained by small sample sizes. This low-sample-size regime exposes variable selection methods to a high risk of overfitting and false d...

M. F. Di Tolla, Domenico Iervolino, Vittorio Scisciola et al. · 0 citations
Open access Oct 2026

Valid Data‐Driven Subgroup Selection With Uniform Guarantees in Clinical Trials

Two recently developed methods for subgroup selection in regression problems are discussed: one based on generalized linear modeling and another on isotonic regression, focusing on two distinct tasks: identifying patient groups that are safe from manifesting adverse events and identifying patient groups with high treat...

Manuel M. Müller, B. Bornkamp, Frank Bretz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.